Vital KSK Holdings, Inc.

3151.T
Medical Distribution
2026/03/02 Updated
Market Cap: $462.0M (¥72.1B)
Stock Price: $9.55 (¥1,490)
Exchange Rate: 1 USD = ¥156.01

(Correction) Partial Correction Regarding “Notice on Expansion of Shareholder Benefit Program”

An error was identified in part of the notice on the expansion of the shareholder benefit program published on 2026-02-26, resulting in corrections to the classification of number of shares held and other details.

Importance:
Page Updated: March 2, 2026
IR Disclosure Date: March 2, 2026

Key Figures

  • Shareholding Classification Before Correction: 100 to less than 300 shares, 300 to 1,000 shares, 1,000 shares or more, 3,000 shares or more
  • Shareholding Classification After Correction: 100 shares or more but less than 300 shares, 300 shares or more but less than 1,000 shares, 1,000 shares or more but less than 3,000 shares, 3,000 shares or more
  • QUO Card Grant Amount: Corrected from 500 yen for 100 shares or more but less than 300 shares up to 5,000 yen for 3,000 shares or more

AI要約

Summary of the Correction

Due to errors found in part of the "Notice on Expansion of Shareholder Benefit Program" announced on 2026-02-26, corrections were made to the classification of number of shares held and descriptions of benefit details. Specifically, the classifications such as "100 to less than 300 shares" and "300 to 1,000 shares" were corrected to accurate classifications such as "100 shares or more but less than 300 shares" and "300 shares or more but less than 1,000 shares," respectively. The QUO card amounts granted as benefits were also corrected to correspond to the appropriate classifications.

Impact on Investors and Future Measures

This correction pertains to errors in the description of the shareholder benefit program, not changes to the program itself. Investors should confirm the corrected shareholder benefit details and understand the benefits corresponding to their number of shares held. The company will continue to strive for appropriate information disclosure going forward.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.